OncRef

Clinical Trial: NCT03391466

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Kite, A Gilead Company
Information Provided By:Gilead Sciences
Last Update Posted:2025-12-01

Study Overview

Brief Summary

The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Official Title

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

Conditions

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Intervention / Treatment

  • Biological: Axicabtagene Ciloleucel
  • Drug: Platinum-containing Salvage Chemotherapy
  • Drug: Cyclophosphamide
  • Drug: Fludarabine

Other Study ID Numbers

  • KTE-C19-107
  • 2017-002261-22
  • 2017

Start Date (Actual)

2018-01-25

Primary Completion Date (Actual)

2021-03-18

Study Completion Date (Actual)

2024-11-25

Enrollment (Actual)

359

Study Type

Interventional

Phase

Phase 3